Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple-B: Atezolizumab + Chemo in TNBC
NCT01898117Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2013
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by Netherlands Cancer Institute. Started Jul 2013; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01898117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01898117.